Focalin XR(TM) Approved for Treatment of ADHD in Adults, Adolescents and Children

Main Category: ADHD
Article Date: 13 Jun 2005 - 0:00 PST

email to a friend   printer friendly   view / write opinions   rate article

The FDA has just approved focalin XR(TM), a new long-acting medication for adults, adolescents and children who struggle with attention- deficit/hyperactivity disorder also known as ADHD. In adults, adolescents and Children, the core symptoms of adhd are inattention, impulsivity and Hyperactivity. Approximately 50 to 70 percent of children with adhd will Continue to experience symptoms into adulthood.

Doctor Lenard Adler, Associate Professor of Clinical Psychiatry and Neurology, NYU School of Medicine:

"Ideally when we're looking for effects of ADHD medication, we're looking for a medicine that will start quickly, have effects throughout the day and this is what Focalin XR has been shown to do. When an adult gets their ADHD treated, a variety of things may improve in their life: their work performance may improve, the quality of their relationships may improve, and their ability to get things done may also get better."

For more information about ADHD treatment with Focalin XR, visit http://www.FocalinXR.com.

NOTE TO PRODUCERS: Like most drugs approved for the treatment of ADHD, Focalin XR is contraindicated in patients known to be hypersensitive to the drug or to methylphenidate, in patients with glaucoma, and in patients with motor tics or with a family history or diagnosis of Tourette's syndrome. It is also contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result). In addition, like most drugs approved for the treatment of ADHD, Focalin XR is a schedule II drug and should be given cautiously to patients with a history of drug dependence or alcoholism.

Novartis Pharmaceuticals
http://www.multivu.com
http://www.FocalinXR.com